SOX11通过PAX5/CD19轴调控BCR信号通路为BTK耐药套细胞淋巴瘤提供治疗靶点
套细胞淋巴瘤(MCL)对BTK抑制剂耐药是临床难题。研究发现SOX11通过转录激活PAX5/CD19轴驱动B细胞受体信号,单细胞RNA测序显示SOX11在伊布替尼耐药患者中过表达。SOX11 DNA结合抑制剂(SOX11i)在伊布替尼敏感和耐药细胞系中降低PAX5、CD19及BCR信号组分表达,在伊布替尼、维奈克拉和CAR-T耐药患者来源异种移植模型中显示细胞毒性,并在MCL异种移植模型中减少肿瘤生长且无明显毒性。
要点
- SOX11通过转录激活PAX5/CD19轴驱动MCL的BCR信号。
- 单细胞RNA测序显示SOX11在伊布替尼耐药患者中过表达。
- SOX11i在伊布替尼敏感和耐药细胞系中降低PAX5、CD19及BCR信号组分。
核心结论
- SOX11通过PAX5/CD19轴驱动BCR信号,抑制SOX11可靶向上游耐药机制,对MCL尤其BTKi耐药患者具有显著潜力。
研究设计与样本
- 研究采用细胞系、患者来源异种移植模型和MCL异种移植模型进行体外和体内实验。
主要发现
- 单细胞RNA测序数据显示SOX11在伊布替尼耐药患者中较伊布替尼敏感患者过表达。
- SOX11i在伊布替尼敏感和耐药细胞系中显著降低PAX5、CD19和BCR信号组分的表达。
- SOX11i在来自伊布替尼耐药、维奈克拉(BCL2抑制剂)和嵌合抗原受体T细胞耐药患者来源异种移植模型的细胞中体外显示细胞毒性。
- SOX11i在MCL异种移植模型中减少体内肿瘤生长且无明显毒性。
临床怎么用
- 作者认为SOX11抑制通过靶向上游耐药机制,对MCL尤其BTKi耐药患者具有显著潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is an incurable subtype of B-cell non-Hodgkin lymphoma. Despite multiple approved Bruton tyrosine kinase inhibitors (BTKis), resistance to BTKi continues to pose a major clinical challenge. The transcription factor sex determining region Y-box 11 (SOX11) is expressed in most patients with MCL and is associated with poor outcomes. We have previously demonstrated SOX11-dependent B-cell receptor (BCR) signaling in transgenic models of MCL. Here, we report that SOX11 drives BCR signaling via the transcriptional activation of the PAX5/CD19 axis. The translational potential of these results is significant as single-cell RNA sequencing data show that SOX11 is overexpressed in ibrutinib-resistant patients as compared to ibrutinib-sensitive patients. Treatment with the SOX11 DNA-binding inhibitor (SOX11i) significantly reduces the expression of PAX5, CD19, and components of BCR signaling in both ibrutinib-sensitive and ibrutinib-resistant cell lines. Importantly, SOX11i was able to demonstrate cytotoxicity in cells derived from ibrutinib-resistant, venetoclax (B-cell lymphoma 2 [BCL2] inhibitor), and chimeric antigen receptor T-cell-resistant patient-derived xenograft models in vitro. SOX11i treatment reduced the tumor growth in vivo in an MCL xenograft model without any significant toxicity. SOX11 inhibition offers significant potential for patients with MCL, especially BTKi-resistant patients, by targeting upstream resistance mechanisms.
引用
- Dutta RP, Lee HH, Leshchenko VV, et al. SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Blood Adv. 2025. PMID: 40845256. doi:10.1182/bloodadvances.2025016801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。